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LIVE, ATTENUATED VACCINES AND 
METHODS OF MAKING AND USING 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
0001. This application claims the benefit of priority under 
35 U.S.C. S 119(e) to U.S. Application No. 61/937,712, filed 
on Feb. 10, 2014. 
TECHNICAL FIELD 
0002 This disclosure generally relates to vaccines. 
BACKGROUND 
0003. Historically, vaccines have been the best weapon 
against the world's deadliest infectious diseases, including 
Smallpox, polio, and yellow fever. Live, attenuated vaccines 
in general tend to elicit the most potent protective immunity, 
since it is the closest mimic of a natural infection. Therefore, 
live, attenuated vaccines elicit strong protective cellular and 
antibody responses and often confer a lifelong immunity 
with only one or two dosings. 
0004. This disclosure provides a novel method for pro 
ducing live-attenuated therapeutic vaccines against a wide 
array of pathogenic viruses or bacteria. 
SUMMARY 
0005 Alive, attenuated vaccine is provided, and methods 
of making a live, attenuated vaccine are provided. 
0006. In one aspect, a live, attenuated HIV vaccine is 
provided, where the genome of the HIV includes at least one 
first mutation in an essential region. Typically, the first 
mutation is a nonsense mutation. 
0007. In some embodiments, the genome of the HIV 
further comprises at least one transgene in a non-essential 
region, the transgene encoding a Suppressor tRNA and a 
corresponding aminoacyl-tRNA synthetase. 
0008. In some embodiments, the genome of the HIV 
further comprises at least one second mutation in an essen 
tial region. Typically, the second mutation results in a codon 
encoding for an unnatural amino acid. In some embodi 
ments, the unnatural amino acid is a photoreactive amino 
acid such as, for example, a photocaged amino acid (e.g., 
ONBK and ONBL). 
0009. In some embodiments, the essential region is the 
gag gene or the protease gene. In some embodiments, the 
non-essential region is between the env gene and the nef 
gene. 
0010. In another aspect, a method of making a live, 
attenuated HIV vaccine is provided. Such a method gener 
ally includes infecting a host cell with a live, attenuated HIV 
vaccine as described herein; and purifying the live, attenu 
ated HIV vaccine. 
0011. In some embodiments, the method further can 
include exposing the infected host cell to light. In some 
embodiments, the light is UV light (e.g., 365 nm light). 
0012. In some embodiments, the host cell includes at 
least one transgene encoding the Suppressor tRNA and the 
corresponding aminoacyl-tRNA synthetase. 
0013. In yet another aspect, an article of manufacture for 
producing a live, attenuated HIV vaccine is provided. Gen 
erally, such an article of manufacture includes a live, attenu 
ated HIV vaccine as described herein; and at least one 
unnatural amino acid (UAA). 
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0014. In some embodiments, the article of manufacture 
further can include a host cell. 
0015. In some embodiments, the host cell includes and 
expresses at least one transgene encoding a first Suppressor 
tRNA and a first corresponding aminoacyl-tRNA synthetase 
pair that recognizes the unnatural amino acid. 
0016. In some embodiments, an article of manufacture 
further can include a photoreactive amino acid. In some 
embodiments, the UAA* is a photoreactive amino acid. 
0017. In some embodiments, the host cell further 
includes at least one transgene encoding a second suppressor 
tRNA and a second corresponding aminoacyl-tRNA syn 
thetase pair that recognizes the photoreactive amino acid. 
0018. Unless otherwise defined, all technical and scien 
tific terms used herein have the same meaning as commonly 
understood by one of ordinary skill in the art to which the 
methods and compositions of matter belong. Although meth 
ods and materials similar or equivalent to those described 
herein can be used in the practice or testing of the methods 
and compositions of matter, Suitable methods and materials 
are described below. In addition, the materials, methods, and 
examples are illustrative only and not intended to be limit 
ing. All publications, patent applications, patents, and other 
references mentioned herein are incorporated by reference in 
their entirety. 
DESCRIPTION OF DRAWINGS 
0019 FIG. 1 is a schematic showing the use of blank 
codons to control HIV replication. Panel A is the structure of 
representative unnatural amino acids (UAA); and Panel B 
is a schematic showing how the replication of HIV is 
controlled using blank codons and UAA*s. 
0020 FIG. 2 is data showing controlled EGFP expression 
in 293T cells. Panel (A) is the chemical structures of 
4-azidophenylalanine (AZF), 4-acetylphenylalanine (AcF). 
and 4-iodophenylalanine (IodoF); Panel (B) is a schematic 
showing EGFP with an Amber codon at position 40; Panel 
(C) demonstrates EGFP expression in the presence of the 
tRNA-AZFRS pair and 1 mM of AZF; Panel (D) demon 
strates EGFP expression in the presence of the tRNA'- 
AZFRS pair, but without AZF. Scale bars, 200 Lum. 
0021 FIG. 3 is data demonstrating that HIV-1 replication 
can be controlled with Amber suppression. Panel (A) shows 
a p24 assay after transfection of 293T with pSUMA variants. 
The absorbance values were determined at 450 nm after the 
colorimetric reactions were stopped by the addition of 1 M 
H2504. Well #11 was used as a blank for all measurements. 
Well #1, wild-type pSUMA only; Well #2, wild-type 
pSUMA+tRNA'-AZFRS pair+1 mM AZF; Well #3, 
pSUMA-Tyr132+tRNA'-AZFRS pair, without AZF; Well 
#4, pSUMA-Tyr132+tRNA-AZFRS pair, with 1 mMAZF; 
Well #5, pSUMA-Tyr132+tRNA'-TyrRS pair; Well #6, 
pSUMA-Tyr132; Well #7, pSUMA-Ala119.--tRNA 
AZFRS pair, without AZF; Well #8, pSUMA-Ala119.-- 
tRNA'-AZFRS pair, with 1 mM AZF; Well #9, pSUMA 
Leu365+tRNA-AZFRS pair, without AZF; Well #10, 
pSUMA-Leu365+tRNA-AZFRS pair, with 1 mM AZF; 
Well #11, negative ELISA control, no p24; Well #12, posi 
tive ELISA control, 125 pg/ml p24; Panels (B)-(I) are data 
from infection assays with TZM-bl cells. Panel (B) shows 
cells infected with virus collected from the sample described 
in Well #1; Panel (C) shows cells infected with virus 
collected from the sample described in Well #2; Panel (D) 
shows cells infected with virus collected from the sample 
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described in Well #4: Panel (E) shows cells infected with 
virus collected from the sample described in Well #3; Panel 
(F) shows cells infected with virus collected from the sample 
described in Well #5; Panel (G) shows cells infected with 
virus collected from the sample described in Well #6; Panel 
(H) shows cells infected with virus collected from the 
sample described in Well #8; Panel (I) shows cells infected 
with virus collected from the sample described in Well #10. 
Scale bars, 100 um. 
0022 FIG. 4 is data showing expression and infection 
with pNL-GI variants. Panel (A) is a fluorescence image of 
pNL-GI; Panel (B) is a fluorescence image of pNL-GI 
Tyra.0+tRNA'-AZFRS pair, with 1 mM AZF; Panel (C) 
shows infection of TZM-bl cells with virus collected from 
the cells shown in FIG. 4, Panel (A); Panel (D) shows 
infection of TZM-bl cells with virus collected from the cells 
shown in FIG. 4, Panel (B). Scale bars, 200 um. 
0023 FIG. 5 is data showing infection assays with TZM 
bl cells. Panel (A) shows cells infected with wild-type 
pSUMA; Panel (B) shows cells infected with pSUMA 
TyrS9; Panel (C) shows cells infected with pSUMA 
Trp36Gln127. Scale bars, 200 um. The doses used for 
infection are shown as Tissue Culture Infectious Dose 50 
(TCID50). The wild-type pSUMA was diluted 4-fold and the 
pSUMA mutants were concentrated 15-fold in order to 
adjust the infectious dose of each variant to a similar level. 
0024 FIG. 6 is data showing p24 assays after transfection 
of 293T with pSUMA variants. Well #1, wild-type pSUMA 
control; Well #2, negative ELISA control, no p24; Well #3, 
positive ELISA control, 125 pg/ml p24; Well #4, pSUMA 
Tyr132+tRNA'-AcFRS pair, with 1 mM AcF: Well #5, 
pSUMA-Alal 19+tRNA'-AclfRS pair, with 1 mM AcF: 
Well #6, pSUMA-Leu365+tRNA"-AcERS pair, with 1 
mM AcF: Well #7, pSUMA-Tyr132+tRNA'-IodoFRS pair, 
with 1 mM IodoF: Well #8, pSUMA-Ala119.--tRNA 
IodoFRS pair, with 1 mM IodoF: Well #9, pSUMA 
Leu365+tRNA'-IodoFRS pair, with 1 mM IodoF. Well #2 
was used as a blank for p24 assays. 
0025 FIG. 7 shows infection assays with TZM-bl cells 
using thNA'-AcFRS pair and tRNA'-IodoFRS pair. 
Panel (A) shows cells infected with virus collected from 
pSUMA-Tyr132+tRNA'-AcERS pair+1 mM AcF; Panel 
(B) shows cells infected with virus collected from pSUMA 
Alal 19+tRNA'-AcERS pair+1 mM AcF: Panel (C) shows 
cells infected with virus collected from pSUMA-Leu365+ 
tRNA'."-AcPRS pair+1 mM AcF; Panel (D) shows cells 
infected with virus collected from pSUMA-Tyr132+ 
tRNA'."-IodoFRS pair+1 mM IodoF; Panel (E) shows cells 
infected with virus collected from pSUMA-Ala 1 19 
tRNA'."-IodoFRS pair+1 mM IodoF: (F) infected with virus 
collected from pSUMA-Leu365+tRNA'."-IodoFRS pair+1 
mM IodoF. Scale bars, 200 um. 
0026 FIG. 8 shows infection assays with TZM-bl cells 
using trNA'"-AZFRS pair. Panel (A) shows cells infected 
with virus collected from pSUMA-Ala119--tRNA-AZFRS 
pair, without 1 mMAZF; Panel (B) shows cells infected with 
virus collected from pSUMA-Leu365+tRNA-AZFRS 
pair, without 1 mMAZF; Panel (C) shows cells infected with 
pSUMA-TyrS9+tRNA-AZFRS pair, without 1 mM AZF 
(the harvested viruses were concentrated 15 folds); Panel 
(D) shows cells infected with pSUMA-Trp36Gln127+ 
tRNA'."-AZFRS pair, without 1 mM AZF (the harvested 
viruses were concentrated 15 folds). Scale bars, 200 um. 
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(0027 FIG. 9 shows mass spectrometry analysis of EGFP 
containing AZF at position 40. They ions are marked in the 
spectrum. The amino acid sequence of the peptide fragment, 
FSVSGEGEGDATAZFGK (SEQ ID NO:23), from mutant 
EGFP containing AZF is shown on top. The amber mutation 
site contained exclusively 4-aminophenylalanine (aminoF), 
which is the reduction product of AZF. This observation is 
consistent with previous reports on the mass spectrometry 
analyses of AZF-containing proteins. 
0028 FIG. 10 is a schematic showing photo-regulation of 
protein function. Panel (A) shows the structures of ONBY 
and ONBK; Panel (B) shows the restoration of protein 
function with UV light. 
0029 FIG. 11 is data demonstrating the incorporation of 
ONBY and ONBK into EGFP-Y40 in 293T cells. Panel (A) 
shows 293T cells containing pEGFP-Y39TAG and pcDNA 
U6-PylT-ONBY in the presence of 0.4 mM ONBY: Panel 
(B) shows 293T cells containing pEGFP-Y39TAG and 
pcDNA-U6-PylTONBY in the absence of 0.4 mMONBY: 
Panel (C) shows 293T cells containing pEGFP-Y39TAG 
and pCMV-ONBK in the presence of 1 mM ONBK; Panel 
(D) shows 293T cells containing pEGFP-Y39TAG and 
pCMV-ONBK in the absence of 1 mM ONBK. 
0030 FIG. 12 is data demonstrating the infectivity of 
pSUMA-d1 d2-AZFRS and pSUMA-d1 d2-TyrRS. Panel (A) 
shows the infection of TZM-bl cells with pSUMA-d1 d2 
AZFRS: Panel (B) shows the infection of TZM-bl cells with 
pSUMA-d1 d2-TyrRS. 
0031 FIG. 13 is data demonstrating EGFP expression 
and infectivity of pSUMA-EGFP mutant. Panel (A) shows a 
fluorescence image of 293T cells containing pSUMA 
EGFP, Panel (B) shows the infection of TZM-bl cells with 
pSUMA-EGFP-derived HIV-1 mutant. 
DETAILED DESCRIPTION 
0032 Genetic code expansion with evolved orthogonal 
suppressor tRNA-aminoacyl-tRNA synthetase (aaRS) pair 
has been widely applied to the site-specific incorporation of 
unnatural amino acids (UAA's) having unique chemical and 
physical properties into proteins in living cells to facilitate 
the study of protein structure and function. This disclosure 
provides a new application for genetic code expansion that 
couples a UAA*-mediated blank codon (i.e., a codon that 
does not encode a natural proteinogenic amino acid) Sup 
pression of the virus assembly process in the development of 
a live, attenuated vaccine. Using this strategy, replication of 
the infectious agent can be precisely controlled by UAA*s, 
thereby creating a live, attenuated vaccine. 
0033. This disclosure describes the use of an unnatural 
amino acid (UAA)-mediated blank codon Suppression sys 
tem (FIG. 1). It is demonstrated herein that introducing 
blank codons within essential regions of the HIV genome 
can prevent the proper translation and assembly of viable 
virus particles. However, live and functional HIV particles 
can be assembled in the presence of a special tRNA 
aminoacyl-tRNA synthetase pair that is able to decode the 
blank codon. The assembled virus particles can be used as a 
live, attenuated vaccine. Since the host does not contain the 
special tRNA-aminoacyl-tRNA synthetase pair, the virus 
can undergo only one cycle of infection and is not able to 
replicate, which attenuates the virus. To make the system as 
stringent as possible, specific tRNA-aminoacyl-tRNA syn 
thetase pairs that only recognize unique UAAs are used. In 
other words, the unique UAA*s are not present in the host 
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and, preferably, are not present in nature. The UAA*- 
mediated blank codon Suppression system described herein 
provides the ability to turn on and off replication cycles of 
the virus in vivo using UAA* as the control element. 
0034) While the fidelity of UAA* incorporation is gen 
erally comparable to the fidelity of amino acid incorporation 
in nature, the possibility remains that the virus could regain 
functional replication by mutating a nonsense codon back to 
a sense codon given the high genetic variability exhibited by 
HIV and viruses in general. Thus, the introduction of more 
than one nonsense codon (e.g., two nonsense codons, three 
nonsense codons, four nonsense codons) into one or more 
essential regions (e.g., two different essential regions) of the 
virus can increase the control over virus replication. Simply 
by way of example, if the virus mutation rate is assumed to 
be approximately 3x10 per nucleotide per cycle of repli 
cation (Rambaut et al., 2004, Nat. Rev. Genet., 5:52-61) and 
the virus life cycle is assumed to be one day, the possibility 
of mutating one or two nonsense codons back to sense 
codons is approximately 1% and 0.01%, respectively, within 
the human life span (for purposes herein, assumed to be 100 
years). In addition, nonsense mutations can be introduced 
into essential regions that exhibit a lower mutation rate, even 
further reducing the likelihood that a mutant would regain 
virulence. 
0035. While HIV was used herein to exemplify the meth 
ods, a similar approach also can be used to generate or 
improve the safety of live, attenuated vaccines for any 
number of infectious viruses or bacteria. 
Live, Attenuated Vaccines and Methods of Making 
0036. The sequence of the human immunodeficiency 
virus (HIV) genome is known and can be found at GenBank 
Accession No. AF033819.3. HIV includes two copies of 
non-covalently linked, un-spliced, positive-sense single 
stranded RNA enclosed by a conical capsid. The RNA 
component is less than 10 kb (i.e., 9749 nucleotides in 
length) and the nucleocapsid associates with the genomic 
RNA (one molecule per hexamer) to protect the RNA from 
attach by nucleases. 
0037. The HIV genome encodes a number of essential 
structural proteins including the group-specific antigen (gag) 
protein, the polymerase (pol) protein, and the envelope (env) 
protein. The gag gene encodes the precursor Gag polypro 
tein that is processed by the viral protease during maturation. 
The pol gene encodes the reverse transcriptase and RNase H 
enzymes, which are required to produce DNA from the RNA 
template, as well as an integrase and a protease. The 
integrase is required to integrate the double-stranded viral 
DNA into the host genome, and the protease is required to 
cleave the precursor Gag polyprotein to produce Some of the 
structural proteins. The env gene encodes gp160, which is 
cleaved by a host protease and results in a surface glyco 
protein that ultimately embeds in the viral envelope and 
enables the virus to attach to and fuse with target cells. 
0038. The HIV genome also contains several essential 
regulatory elements including the HIV trans-activator (tat) 
and the regulator of expression of virion proteins (rev). The 
tat protein plays an important role early in HIV infection in 
regulating the reverse transcription of viral genome RNA, 
ensuring efficient synthesis of viral mRNAS and regulating 
the release of virions from infected cells. Given its role in 
infection and transcription, the tat protein is essential for the 
survival of HIV. The rev protein binds to the viral genome 
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via an arginine-rich RNA-binding motif that also acts as a 
nuclear localization signals (NLS), which results in the 
transport of the rev protein into the nucleus during viral 
replication. The rev protein is important for the synthesis of 
major viral proteins and is hence essential for viral replica 
tion. 
0039. In addition, the HIV genome contains a number of 
accessory regulatory proteins that generally are considered 
non-essential to the virus. Accessory regulatory proteins 
include the lentivirus protein R (vpr), the negative factor 
(nef) protein, the viral infectivity factor (vif), and the virus 
protein U (vpu). The Vpr protein is a virion-associated, 
nucleocytoplasmic shuttling regulatory protein. It is 
believed to play an important role in replication of the virus, 
specifically, nuclear import of the pre-integration complex. 
The Vpr protein also appears to cause its host cells to arrest 
their cell cycle in the G2 phase, which activates the host 
DNA repair machinery to enable integration of the viral 
DNA. In addition, the nef protein is a N-terminal myristoy 
lated membrane-associated phosphoprotein involved in mul 
tiple functions during the replication cycle of the virus 
including, for example, apoptosis and increasing virus infec 
tivity. The Vif protein is a highly conserved, 23 kDa phos 
phoprotein important for the infectivity of HIV-1 virions 
depending on the cell type, and the Vpu protein is a class I 
oligomeric integral membrane phosphoprotein with numer 
ous biological functions. 
0040. As indicated herein, an unnatural amino acid 
(UAA)-mediated blank codon Suppression system (FIG. 1) 
has been developed and used to prevent the proper transla 
tion and assembly of viable virus particles by introducing at 
least one (e.g., one or more; e.g., at least two, at least three) 
UAA*-mediated blank codons into one or more essential 
regions of the HIV virus. It would be appreciated by a skilled 
artisan that UAA*-mediated blank codons also can be 
referred to as “nonsense mutations.” As used herein, a 
“nonsense mutation” refers to a mutation that produces a 
codon (e.g., an amber codon, an ochre codon, an opal or 
umber codon) that does not encode a natural proteinogenic 
amino acid. As described herein, however, the system allows 
for assembly of live and functional HIV particles in the 
presence of a corresponding tRNA, referred to herein as a 
“suppressor tRNA. For the suppressor tRNA to be present 
and capable of decoding the blank codon, the system further 
requires the corresponding aminoacyl-tRNA synthetase 
(aaRS). It would be understood that the corresponding 
suppressor tRNA and aminoacyl-tRNA synthetase often 
times are referred to as a “pair.” 
0041. Two systems, E coli tRNA'-tyrosyl-tRNA syn 
thetase (TyrRS) pair and archaeal tRNA-pyrrolysyl-tRNA 
synthetase (PylRS) pair, have been developed to decode 
either nonsense (Liu et al., 2007, Nat. Methods, 4:239-44: 
Chen et al., 2009, Angew. Chem. Int. Ed., 48:4052-5; Wang 
et al. 2007, Nat. Neurosci., 10:1063-72) or frameshift (Niu 
et al., 2013, ACS Chem. Biol. 8:1640-5) codons in mam 
malian cells. However, the complicated assembly process of 
human viruses has made it very challenging to genetically 
incorporate mutations, and particularly nonsense mutations, 
into the proteins of live human viruses using either of the 
above two systems. This disclosure, however, has accom 
plished that feat. 
I0042 Specifically, as described herein, a tRNA'-4-azi 
dophenylalanyl-tRNA synthetase (AZFRS) pair, a tRNA'- 
4-acetylphenylalanyl-tRNA synthetase (AcFRS) pair, and a 
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tRNA"-4-iodophenylalanyl-tRNA synthetase (IodoFRS) 
pair (see, for example, Liu et al., 2007, Nat. Methods, 
4:239-44) were used. All three amino acids have similar 
sizes to that of tyrosine, and the AZF and AcF molecules 
(FIG. 2A) also contain unique functional groups that allow 
selective modification of viral proteins through bioorthogo 
nal reactions. The methods and systems described herein, 
however, are not limited to either an Ecoli tRNA"-tyrosyl 
tRNA synthetase (TyrRS) pair or an archaeal tRNA 
pyrrolysyl-tRNA synthetase (PylRS) pair; the methods and 
systems described herein are amenable to virtually any 
suppressor tRNA-aminoacyl-tRNA synthetase pair that are 
identified or designed. 
0043. The HIV genome can be engineered to contain 
multiple and different mutations within one or more essen 
tial regions, which further attenuates and controls the virus. 
For example, a second mutation can be a mutation that 
encodes for a second unnatural amino acid (UAA) within 
the same or a different essential region. In some embodi 
ments, a second or further mutation can encode, for 
example, a photoreactive amino acid. Photoreactive amino 
acids are known in the art and include, for example, pho 
tocaged amino acids (e.g., ONBK, ONBL) that, upon expo 
Sure to light of a particular wavelength, revert to the natural 
amino acid. 
0044. A mutation as described herein can be the result of 
a point mutation, an insertion, a deletion, a substitution, or 
combinations thereof. Introducing a mutation into a 
sequence is known in the art, and one or more mutations can 
be introduced into a viral genome using routine methods 
Such as, without limitation, PCR-mediated mutagenesis or 
other recombinant nucleic acid techniques (e.g., restriction 
enzyme digestion, chemical synthesis, ligation, and combi 
nations thereof). 
0045. To suppress a mutation as described herein (e.g., a 
nonsense mutation), the suppressor tRNA-aminoacyl-tRNA 
synthetase pair can be provided on at least one transgene, 
operably linked to one or more expression elements. Expres 
sion elements include nucleic acid sequences that direct and 
regulate expression of coding sequences. One example of an 
expression element is a promoter sequence. Expression 
elements also can include introns, enhancer sequences, 
response elements, or inducible elements that modulate 
expression of a nucleic acid. Expression elements can be of 
viral origin or bacterial, yeast, insect, or mammalian origin, 
and transgenes or vectors containing one or more transgenes 
can contain a combination of expression elements from 
different origins. 
0046. It would be appreciated by a skilled artisan that the 
one or more transgenes encoding a Suppressor tRNA and the 
corresponding aminoacyl-tRNA synthetase can be contained 
within one or more vectors. Vectors, including expression 
vectors, are commercially available or can be produced by 
recombinant DNA techniques routine in the art. A vector 
containing a nucleic acid can have expression elements 
operably linked to such a nucleic acid, and further can 
include sequences such as those encoding a selectable 
marker (e.g., an antibiotic resistance gene). As used herein, 
operably linked means that a promoter or other expression 
element(s) are positioned relative to a coding sequence so as 
to direct or regulate expression of the nucleic acid (e.g., 
in-frame). 
0047 One or more vectors containing at least one trans 
gene (i.e., encoding a Suppressor tRNA and corresponding 
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aminoacyl-tRNA synthetase pair) can be introduced into a 
host cell. As used herein, “host cell refers to the particular 
cell into which the nucleic acid is introduced and also 
includes the progeny of Such a cell that carry the vector. A 
host cell can be a prokaryotic or eukaryotic cell. For 
example, a transgene as described herein can be expressed 
in bacterial cells such as E. coli, or in yeast, plant cells, or 
mammalian cells (e.g., human 293T cells). Other suitable 
host cells are known to those skilled in the art. Many 
methods for introducing nucleic acids into host cells, both in 
vivo and in vitro, are well known to those skilled in the art 
and include, without limitation, electroporation, calcium 
phosphate precipitation, polyethylene glycol (PEG) trans 
formation, heat shock, lipofection, microinjection, and viral 
mediated nucleic acid transfer. In some cases, the choice of 
methods will depend upon whether integration into the 
genome of the host cells is desired or required, or whether 
transient expression or extrachromosomal expression from a 
vector (e.g., a replicating plasmid) is desired. 
0048 Alternatively, and as discussed herein, the at least 
one transgene (e.g., at least two transgenes, at least three 
transgenes) encoding the Suppressor tRNA and correspond 
ing aminoacyl-tRNA synthetase pair can be introduced into 
the HIV genome. In this embodiment, the at least one 
transgene is introduced into a non-essential region of the 
HIV genome that allows transcription and translation and 
does not interfere with replication and packaging. It would 
be appreciated that, from a safety perspective, expression of 
the suppressor tRNA and corresponding aminoacyl-tRNA 
synthetase pair from the HIV genome requires that the 
nonsense mutation encodes for an amino acid that does not 
exist in the host and, preferably, does not exist in nature. 
0049 Methods of maintaining a live, attenuated HIV 
vaccine are known in the art, and typically include infecting 
a host cell with the live, attenuated HIV vaccine. The host 
cell, under these circumstances, typically is determined by 
the virus host specificity. As discussed herein, if the viral 
genome does not contain a transgene encoding the Suppres 
sor tRNA and corresponding aminoacyl-tRNA synthetase 
pair, then the at least one transgene encoding the Suppressor 
tRNA and corresponding aminoacyl-tRNA synthetase pair 
needs to be provided by the host cell in order to suppress the 
mutation. In addition, if any of the mutations include a 
photoreactive amino acid, then the appropriate light needs to 
be provided in order to suppress the mutation. Following 
infection, the live, attenuated HIV vaccine described herein 
can be purified. As used herein, purifying a live, attenuated 
HIV vaccine refers to a process that removes the vaccine 
from the host cell or from the culture in which the host cell 
is growing. 
0050. In addition, an article of manufacture if provided 
for producing or maintaining a live, attenuated HIV vaccine. 
An article of manufacture as described herein can include a 
live, attenuated HIV vaccine as described herein, and at least 
one unnatural amino acid (UAA). An article of manufac 
ture also can include an appropriate host cell, which, if 
necessary, includes the at least one transgene encoding the 
suppressor tRNA and the corresponding aminoacyl-tRNA 
synthetase pair that recognizes the unnatural amino acid. In 
Some embodiments, an article of manufacture can include 
one or more (e.g., two or more, three or more) photoreactive 
amino acids and, if necessary, at least one transgene encod 
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ing the Suppressor tRNA and the corresponding aminoacyl 
tRNA synthetase pair that recognizes the photoreactive 
amino acid. 
0051. In accordance with the present invention, there 
may be employed conventional molecular biology, micro 
biology, biochemical, and recombinant DNA techniques 
within the skill of the art. Such techniques are explained 
fully in the literature. The invention will be further described 
in the following examples, which do not limit the scope of 
the methods and compositions of matter described in the 
claims. 
EXAMPLES 
Example 1 
General 
0052 All chemicals and DNA oligomers were obtained 
from commercial sources and used without further purifi 
cation. 
0053. Unnatural amino acids (UAA*s), 4-azidophenyl 
alanine (AZF) and 4-iodophenylalanine (IodoF), were pur 
chased from Bachem. The synthesis of 4-acetylphenylala 
nine (AcF) follows the procedure that was previously 
reported (Wang et al., 2003, PNAS USA, 100:56-61). 
0054 HIV-1 clone, pSUMA.c/2821, Catil 11748, referred 
to herein as “pSUMA”, is an infectious molecular clone of 
a founder/transmitter HIV-1 virus and was obtained through 
the NIH AIDS Reagent Program, Division of AIDS, NIAID, 
NIH, from Dr. John Kappes and Dr. Christina Ochsenbauer. 
0055 E. coli DH10B and GeneHogs were used for rou 
tine cloning and DNA propagation. E. coli Stb1-2 (Life 
Technologies) was use for pSUMA manipulations. 
0056 Standard molecular biology techniques (Sambrook 
et al., 2000, Molecular Cloning: A Laboratory Manual. Third 
Ed., Cold Spring Harbor Laboratory Press) were used 
throughout. 
Example 2 
Plasmid Construction 
0057 pcDNA3.1-tRNA'": 
0058. The suppressor tRNA" was derived from E. coli. 
The G35 of the tRNA" was mutated to C to generate CUA 
anticodon. The tRNA' gene lacking 3'-CCA but with a 
3'-TTTTTCT sequence was PCR amplified. A human U6 
promoter was PCR amplified from pCMV-pylRSNBK-1 
(Chen et al., 2009, Angew. Chem. Int. Ed., 48:4052-5 and 
121:4112-5) and added in front of the tRNA gene by 
overlapping PCR. The U6-tRNA' gene cassette was PCR 
amplified and inserted into pcDNA3.1/hygro(+) (Life Tech 
nologies) in front of the CMV promoter to afford pcDNA3. 
1-tRNA'. 
0059 pAZFRS: 
0060. The AZFRS-encoding gene was PCR amplified 
from plasmid pSWAN-pAZpaRS (Liu et al., 2007, Nat. 
Methods 4:239-44) and inserted into pcDNA3.1-tRNA'." 
behind the non-regulated CMV promoter to afford plasmid 
pAZFRS. 
0061 pAcFRS: 
0062. The AcFRS-encoding gene was PCR amplified 
from plasmid pSWAN-pApaRS (Liu et al., 2007, Nat. Meth 
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ods 4:239-44) and inserted into pcDNA3.1-tRNA" behind 
the non-regulated CMV promoter to afford plasmid pac 
FRS. 
0063 plodoFRS: 
0064. The IodoFRS-encoding gene was PCR amplified 
from plasmid pSWAN-plpaRS (Liu et al., 2007, Nat. Meth 
ods 4:239-44) and inserted into pcDNA3.1-tRNA" behind 
the non-regulated CMV promoter to afford plasmid plod 
OFRS. 
0065 pEGFP-TAG40: 
0066. The EGFP-encoding gene containing an amber 
stop codon (UAG) at a permissive site (Tyr20) was inserted 
into pcDNA3.1-tRNA' behind the non-regulated CMV 
promoter to afford plasmid plGFP-TAG40. 
0067 pSUMA Mutants: 
0068. Overlapping PCR was used to introduce amber 
mutations onto the HIV-1 genome that is encoded by plas 
mid pSUMA. The following primers were used to introduce 
amber mutations: 
pSUMA-Tyr132 
(SEQ ID NO: 1) 
5 - CTAGAACGATTCGCAGTTAACCCTG-3 
(SEQ ID NO: 2) 
s' - GTTCTGCACTATAGGCTAATTTTGGCTGACCTGGCTG-3' 
(SEQ ID NO : 3) 
5-TAGCCTATAGTGCAGAACCTCCAG-3 
(SEQ ID NO : 4) 
s' - GTGCCTATAGCTTTGTGTCCACAG-3' 
pSUMA-Alal19 
(SEO ID NO; 5) 
5 - CTAGAACGATTCGCAGTTAACCCTG-3 
(SEQ ID NO : 6) 
5'-TTTCCTGCGTCAGCCtaTGCTTGCTGTGCTTTTTTCTTAC-3' 
(SEO ID NO: 7) 
5 - CTGACGCAGGAAACAACAGCCAG-3' 
(SEQ ID NO: 8) 
s' - GTGCCTATAGCTTTGTGTCCACAG-3' 
pSUMA-Leu365 
(SEO ID NO: 9) 
5 - CAAAGTAAGACAATATGATCAGGTAAC-3' 
(SEQ ID NO: 10) 
s" - CACCTCTACAGATGTTCTCTCAGTTCCTC-3' 
(SEQ ID NO: 11) 
5 - CATCTGTAGAGGTGGGGATTTACCACAC-3' 
(SEQ ID NO: 12) 
5'-GCTTCCCATGTTTCTCTTTGTATG-3 
pSUMA-Tyr59 
(SEQ ID NO: 13) 
5 - CTAGAACGATTCGCAGTTAACCCTG-3 
(SEQ ID NO: 14) 
5'-ATTTCTATGGTTACCTGATCCTATTGTCTTACTTTGATAAAAC-3' 
pSUMA-Trp36Gln127 
(SEQ ID NO: 15) 
5 - GTAGAGGATCCACTAGTAAC-3' 
(SEQ ID NO: 16) 
5'-TAGCTCCCTGCTTGCCTATACTATATGTTTTAATTG-3' 
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- Continued 
(SEO ID NO: 17) 
5 " - GGCAAGCAGGGAGCTAGAAC-3 
(SEQ ID NO: 18) 
s' - GTGCCTATAGCTTTGTGTCCACAG-3' 
0069 pNL-GI-Tyr-10: 
0070. Overlapping PCR was used to introduce amber 
mutations onto the GFP gene that is encoded on plasmid 
pNL-GI (Collins et al., 1998, Nature, 391:397-401). The 
following primers are used to introduce the amber mutation: 
(SEQ ID NO: 19) 
5 - GCTATAAGACGCGTCCACCATG-3 
(SEQ ID NO: 2O) 
s' - CCTAGGTGGCATCGCCCTC-3' 
(SEQ ID NO: 21) 
5 - CGATGCCACCTAGGGAAAGCTGACCCTGAAGTTC-3' 
(SEQ ID NO: 22) 
s' - CGTCTAGATTACTTGTACAGCTCATC-3' 
Example 3 
Protein Expression and Purification 
0071) 293T cells were grown in media containing 
DMEM, 10% FBS (v/v), and 2 mM L-glutamine at 37° C. 
in a humidified atmosphere of 5% CO (v/v). When cells 
reached 60-70% confluency, they were transfected with 
plasmids pEGFP-40TAG and pAZFRS using Lipo 
fectamineTM 2000 (Life Technologies) according to the 
manufacturer's protocol (36 uL Lipofectamine 2000+12 lug 
of p AZFRS+12 ug of pEGFP-TAG40 for 12 mL cell culture 
in 75 cm cell-culture flask). Six hours posttransfection, the 
culture medium was carefully removed and replaced with 12 
ml of fresh medium containing 1 mMAZF. Cells were grown 
for an additional 36 h before being washed with DPBS, 
lysed with RIPA buffer (Thermo Scientific), and partially 
purified using Ni-NTA resin (GE Healthcare) according to 
the manufacturer's protocol. 
Example 4 
Transfection and Generation of Live HIV-1 
0072 293T cells were grown in a medium containing 
DMEM, 10% FBS, and 2 mM L-glutamine at 37° C. in a 
humidified atmosphere of 5% CO. When cells reached 
60-70% confluency, they were transfected with appropriate 
plasmid(s) using Lipofectamine 2000 (10 ul Lipofectamine 
2000+3 ug of plasmid(s) for 2 ml cell culture in a 6-well 
plate) by following standard procedures provided by the 
manufacture (Life Technologies). Six hours posttransfec 
tion, the culture medium was carefully removed and 
replaced with 2 ml of fresh medium. When it was needed, 
UAA was added to a final concentration of 1 mM. After 
44-48 hours of incubation, virus-containing culture Super 
natant was harvested by collecting the medium from the well 
using a pipette. The FBS concentration in the virus-contain 
ing culture medium was then adjusted to 20% (i.e. for each 
1 ml of harvested virus, 0.125 ml of FBS was added). The 
virus-containing culture medium was then filtered through a 
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0.45-micron filter. The virus was used directly or aliquoted 
into sterile screw-cap vials and stored at -80° C. 
Example 5 
p24 Assay 
(0073 P24 assay was measured with Retrotek HIV-1 p24 
Antigen ELISA 2.0 by following standard procedures pro 
vided by the manufacture (ZeptoMetrix Corporation). 
Briefly, 200 ul cell culture samples, the standard, and the 
control were added to the monoclonal antibody-coated 
micro-plate wells and incubated at 37°C. for 1.5 hour. After 
washing and the addition of antibody-HRP conjugate, the 
micro-plate was incubated at 37° C. for one hour. Plates 
were then washed and the HRP-substrate was added for 
color development. The reactions were stopped by the 
addition of 1 M H2504 and absorbance values were deter 
mined at 450 nm. The amount of p24 is determined by 
interpolation from a point-to-point plot or from a linear 
regression analysis of the standard curve. 
Example 6 
Infection Assay 
0074 HIV-1 infection was quantified with X-gal staining 
based assay with TZM-bl cells. Briefly, virus (generated in 
the presence of UAA*), 50 ul 10% DMEM growth medium, 
and DEAE-dextran at a final concentration of 40 mg/ml 
were added to each well (96-well flat bottom plate) that 
contains TZM-bl cells (1x10" per well in 100 ul volume) in 
triplicate. Assay controls included: (1) replicate wells of 
TZM-bl cells with virus that are generated in the absence of 
UAA*; (2) growth medium only control; and (3) TZM-bl 
cell only control. After 48-hour incubation at 37°C., 200 ul 
of assay medium was removed from each well. Plates were 
then washed, fixed, and stained using X-gal Solution fol 
lowed by examination using a light microscope. 
Example 7 
Tissue Culture Infectious Dose 50 (TCID50) 
(0075 Infectious titers of all viruses were determined by 
standard Tissue Culture Infectious Dose 50 (TCID50) 
method with X-gal staining assay (see above) in TZM-bl 
cells. Briefly, four-fold serial dilutions of virus were per 
formed in quadruplicate (96-well flat bottom plate) in the 
X-gal staining assay. The TCID50 of the virus was calcu 
lated by Spearman-Karber formula according to the negative 
end-point and dilution folds. 
Example 8 
Fluorescence Spectroscopy and Cell Imaging 
0076. The fluorescent images and bright-filed images 
were taken by a Nikon ECLIPSE TE3000 microscope and an 
EVOS FL Auto Imaging System with DIC. The cells were 
excited at 488 nm to acquire EGFP fluorescence images at 
530/25 nm. 
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Example 9 
LC/MS/MS Assays 
0077. The corresponding protein band of EGFP-40TAG 
from SDS-PAGE was cut and in-gel digested with trypsin (in 
50 mMammonium bicarbonate, pH 8.0) overnight at 37°C. 
The resulting peptide fragments were extracted with 0.1% 
formic acid/75% acetonitrile, and then subjected to LC/MS/ 
MS analysis using a Waters Q-TOF Ultima. Database 
searches were performed on an in-house Mascot server 
(Matrix Science Ltd., London, UK). For AZF substitution 
site mapping on EGFP. AZF substitution for tyrosine was 
included as a variable modification. 
Example 10 
Suppression Efficiency and Fidelity 
0078. To examine the nonsense (e.g., amber) suppression 
efficiency and fidelity of the tRNA-AZFRS pair, 293T 
cells were co-transfected with a plasmid containing tRNA'." 
under the control of a human U6 promoter and the AZFRS 
(pAZFRS) with a plasmid encoding EGFP with an amber 
mutation at residue 40 (pl.GFP-TAG40). Following trans 
fection, cells were cultured in DMEM media (containing 
10% FBS and 2 mM L-glutamine) with or without 1 mM 
AZF for 12 h before visualization under a fluorescence 
microscope (FIGS. 2C and 2D). Full-length EGFP was 
detected only in cells supplemented with 1 mM AZF (FIG. 
2C), while no EGFP was observed otherwise (FIG. 2D). The 
tandem mass spectrometry data (FIG. 9) showed no unde 
sirable incorporation of tyrosine or any other natural amino 
acids. The amber mutation site contained exclusively 
4-aminophenylalanine (aminoF), which is the reduction 
product of AZF. These results confirmed the excellent fidel 
ity of AZF incorporation, and are consistent with previous 
reports on the mass spectrometry analyses of AZF-contain 
ing proteins. 
Example 11 
Suppression of the Gag Protein 
007.9 The suppression of an amber codon in the HIV-1 
genome was examined next. The Tyr132 codon on the Gag 
(group-specific antigen) protein-encoding gene was first 
mutated into an amber codon. The resulting pSUMA-Tyr132 
was co-transfected into 293T cells with plasmid paZFRS. 
After the cells were grown for 48 h in the presence or the 
absence of 1 mM AZF, viruses were harvested and the titer 
of HIV-1 was analyzed using anti-p24 antibody. The pres 
ence and the strength of a blue color Suggest the presence 
and the level of the capsid protein p24. As shown in FIG.3A 
(Wells #3 and #4), we observed an AZF-dependent p24 
synthesis in pSUMA-Tyr132 mutant due to the essential role 
of Gag (Gag is processed during maturation to p24.) in p24 
protein synthesis. The p24 assay confirmed a very high 
fidelity of AZF incorporation (absorbance values of 0.001 
versus 0.453 in the absence and the presence of AZF. 
respectively; FIG. 3A, Wells #3 and #4). However, only very 
low level of p24 synthesis was observed comparing to that 
of the wild-type pSUMA control (FIG.3A, Well #1). On the 
other hand, a very strong p24 synthesis was observed with 
the tRNA'-AclRS pair (FIG. 6, Well #4) and an undetect 
able p24 synthesis was observed with the tRNA'-IodoFRS 
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pair (FIG. 6, Well #7). Despite amber suppression and the 
synthesis of p24, little to no viral infection was observed 
when the harvested viruses were used to infect TZM-bl cells 
(FIG. 3D and FIGS. 7A, 7D: The TZM-bl cell line stably 
expresses large amounts of CD4 and CCR5 and should be 
highly sensitive to infections by diverse isolates of HIV-1. 
The TZM-bl also contains a genome-copy of beta-galacto 
sidase gene under the control of the HIV-1 promoter. The 
infection assay is based on the expression level of beta 
galactosidase). 
0080. To explain the lack of live HIV-1 assembly from 
the above experiments, we first examined whether amber 
Suppression can negatively affect HIV-1 protein syntheses, 
the virion assemble, and/or the infection since HIV-1 uses 
seven amber codons as stop signal. To this end, wild-type 
pSUMA was co-transfected with plasmid paZFRS into 
293T cells. After 48 h of cultivation in the presence of 1 mM 
AZF, viruses were harvested and the titer of HIV-1 was 
analyzed using anti-p24 antibody. We observed no obvious 
difference in p24 synthesis (FIG. 3A, Wells #1 and #2) and 
infection rate (FIGS. 3B and 3C) of wild-type pSUMA in the 
presence or the absence of the amber suppressing tPNA'"- 
AZFRS pair. To further eliminate the possibility, we con 
structed a different HIV-1 mutant that was derived from 
pNL-GI (Collins et al., 1998, Nature, 391:964-7), which 
contains a copy of GFP inserted at the nef locus. In this new 
HIV-1 construct, an amber mutation was made at position 40 
of GFP (originally encoding a tyrosine residue) and there 
was no amber mutation on the HIV-1 protein-encoding 
genes. The resulting HIV-1 variant, pNL-GI-Tyr10, was 
transfected into 293T cells together with plasmid paZFRS. 
Strong GFP fluorescence (FIG. 4B) was detected when 1 
mM of AZF was included in the culture medium. The 
fluorescence intensity is comparable to the wild-type pNL 
GI (FIG. 4A), which indicated a very efficient amber Sup 
pression with the tRNA'-AZFRS pair. The produced HIV-1 
viruses were then harvested and used to infect TZM-bl cells. 
Near wild-type infection was observed (FIGS. 4C and 4D). 
Based on the above observations, we concluded that amber 
suppression did not have detectable detrimental effects on 
the viability of HIV-1. 
I0081. It was then tested to see if UAA* incorporation at 
Tyr132 of Gag protein interfered with either the proper 
function or the post-translational processing of the Gag 
protein. To this end, the pSUMA-Tyr132 mutant was trans 
fected into 293T cells with a plasmid containing trNA'- 
TyrRS pair. The amber suppression led to the incorporation 
of a tyrosine residue at position 132, which produced the 
wild-type Gag protein. The p24 (FIG. 3A, Well #5) and 
infection (FIG. 3F) assays showed that the pSUMA-Tyr132 
mutant, after amber Suppression, had near wild-type activi 
ties. As a control, when pSUMA-Tyr132 was transfected 
into 293T cells that did not contain the tRNA'-TyrRS pair, 
no p24 synthesis was detected (FIG. 3A, Well #6) and no 
live viruses was assembled according to the infection assay 
(FIG. 3G). Combining these results and the results from 
UAA* incorporation, we concluded that incorporation of 
UAA* at position Tyr132 must have negative effect on the 
Gag protein expression and/or function. 
Example 12 
Suppression of the Gag or Pol Protein 
0082 We next decided to examine other mutation sites 
and generated two new HIV-1 mutants, with amber mutation 
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at Alal 19 of Gag (pSUMA-Ala119) or Leu365 of Pol 
(pSUMA-Leu365). We initially focused on the amber sup 
pression with the tRNA'."-AZFRS pair in the presence of 
AZF. We observed an AZF-dependent p24 synthesis in 
pSUMA-Alal 19 (FIG. 3A, Wells #7 and #8). The amber 
suppression at Ala119 position (FIG. 3A, Well #8) was 
apparently stronger than that at position Tyr132 of Gag 
(FIG. 3A, Well #4) and has similar good fidelity (absorbance 
values of 0.000 versus 2.127 in the absence and the presence 
of AZF, respectively; FIG. 3A, Wells #7 and #8). On the 
other hand, the synthesis of p24 in pSUMA-Leu365 was not 
AZF-dependent (FIG.3A, Wells #9 and #10) since the amber 
mutation is in Pol, which does not affect p24 synthesis. Both 
mutants showed infection (FIGS. 3H and 31) but with much 
lower activity than that of wild-type pSUMA (FIG. 3B). As 
a control, no infection was observed when AZF was not 
provided in the culture medium of 293T cells after trans 
fection (FIGS. 8A, 8B). We next examined the tRNA 
AcFRS pair and tRNA'-IodoFRS pair. As shown in FIG. 
6, a range from non-detectable to relative strong amber 
suppression was observed with the two tRNA-aaRS pairs 
and the different amber mutation sites (FIG. 6, Wells #5, #6, 
#8, and #9). However, no infection was detected when the 
tRNA'-AcPRS pair and tRNA'."-IodoFRS pair were used 
to generate pSUMA-Ala 119 and pSUMA-Leu365 mutants 
(FIGS. 7B, 7C, 7E, and 7F). Since the amber suppression 
efficiency did not correlate well with the infection results, 
we suspected that the structure of UAA*s and the incorpo 
ration sites might still partially interfere with the protein 
function. 
Example 13 
Suppression of the Protease Protein 
I0083. An additional mutation site, TyrS9TAG (pSUMA 
TyrS9) of HIV-1 protease was then examined. Since TyrS9 
has similar structure to AZF and is away from the active site 
(PDB 1 EBZ), mutation of which to AZF might not cause 
undesired disturbance of protein structure and function. 
Indeed, the pSUMA-TyrS9 mutant showed better infection 
activity (FIG. 5B) than that of the pSUMA-Alal 19 (FIG. 
3H) and pSUMA-Leu365 (FIG. 3I). As a control, no live 
pSUMA-TyrS9 virus was produced in the absence of AZF 
during viral assembly in 293T cells according to the infec 
tion assay (FIG. 8C). A comparison between the observed 
Tissue Culture Infectious Dose 50 (TCID50) values in the 
presence (1.31x103) and the absence of AZF (0.00) impli 
cates high fidelity of the tRNA-AZFRS pair. 
0084. The results above indicate that the UAA*-mediated 
Suppression strategy can be used to produced live HIV-1 and 
the resulting virus is infectious. Since the infected cells do 
not contain the necessary Suppression machinery (the special 
tRNA-aaRS pair and UAA*) that is required for HIV-1 
assembly, no new virus can be assembled after the initial 
infection. 
Example 14 
All-in-One pSUMA Vector for In Vivo Experiments 
0085. In order to further examine the feasibility of con 
trolling multiple cycles of HIV-1 replication with unnatural 
amino acid-mediated amber Suppression, we needed to gen 
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erate HIV-1 mutants that contain a genomic insertion of an 
amber Suppressor tRNA and its corresponding aminoacyl 
tRNA synthetase. 
I0086 According to previous reports, the nefregion of the 
HIV-1 genome tolerates deletions and/or insertions. We have 
obtained pSUMA-d1 d2 constructs in which two regions of 
the nef gene were deleted. We examined the infectivity of 
pSUMA-d1 d2 in humanized-BLT mice and demonstrated 
that pSUMA-d1 d2 has near wild-type infectivity. 
I0087. We next constructed pSUMA-d1 d2-U6-tRNA by 
inserting U6-promoter-RNA-terminator cassette into the 
deleted nef region of HIV-1 genome. We also constructed 
pSUMA-d1 d2-AZFRS and pSUMA-d1 d2-TyrRS by insert 
ing AZRS (for the incorporation of p-azido-phenylalanine) 
and TyrRS (for the incorporation of tyrosine), respectively, 
into the nef region of the HIV-1 genome. All three modified 
viruses showed weak infection. The results indicated that 
insertion into the nefregion of genes of this size reduces the 
infectivity of virus. 
I0088 Since gene insertion in the nef region is not well 
tolerated, we next focused on a region between env and nef. 
A model viral genome, pSUMA-EGFP, was constructed by 
inserting an EGFP gene between the env and the nef region. 
After transfection, cells containing pSUMA-EGFP showed 
strong green fluorescence. The result indicated that the 
inserted EGFP could be successfully expressed. Next, we 
infected TZM-bl cell with pSUMA-EGFP-derived virus. A 
comparable infectivity to that of wild-type HIV-1 was 
observed. These results indicated that a large gene could be 
inserted between env and nef with no apparent effects on 
virus replication and infection. 
I0089 pSUMA-AZFRS and pSUMA-TyrRS have been 
constructed and are evaluated, in the presence of a corre 
sponding aminoacyl-tRNA synthetase, in humanized-BIT 
1CC. 
Example 15 
HIV Containing Two Amber Mutations 
0090. To examine if the suppression of two amber codons 
on the HIV-1 genome by the tRNA'-AZFRS pair is suffi 
ciently attenuated but still able to efficiently produce mean 
ingful amounts of live HIV, an HIV-1 mutant was con 
structed having two amber mutations, Trp36 and Gln127 
within the matrix domain (MA) of the Gag protein 
(pSUMA-Trp36Gln127). The positions were selected using 
the crystal structure of the MA protein (see PDB: 2H3F) and 
because they are not key residues for MAs interaction with 
phosphatidylinositol 4,5-bisphosphate. In addition, these 
mutation sites are located relative early on the HIV-1 
genome, which reduces the chance of interference with the 
alternative reading frame and post-translational processing 
of the HIV proteins. Encouragingly, similar infection activ 
ity was observed with pSUMA-Trp36Gln127 (FIG. 5C) 
compared to an HIV-1 containing a single amber mutation 
(FIG. 5B). As a control, no live pSUMA-Trp36Gln127 virus 
was produced in the absence of AZF during viral assembly 
in 293T cells according to the infection assay (FIG. 8D). 
Example 16 
Light-Activated Replication of HIV-1 
0091 To add an additional regulatory element to control 
HIV-1 replication, HIV-1 mutants were generated that only 
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replicate in the presence of 365 nm UV light. As shown in 
FIG. 10, an essential tyrosine or lysine residue in an HIV-1 
protein is genetically replaced with o-nitrobenzyl-O-tyro 
sine (ONBY) or o-nitrobenzyl-oxycarbonyl-Ne-L-lysine 
(ONBK), respectively. With exposure to UV light, ONBYor 
ONBK is converted back to tyrosine or lysine, respectively, 
and the function of the protein is restored. 
0092. To examine the fidelity and efficiency of the 
genetic incorporation of ONBY and ONBK, the expression 
level of EGFP-Y39TAG, which contains an amber codon at 
position 39, was examined. As shown in FIG. 11, strong 
green fluorescence was only observed in samples Supple 
mented with ONBY (FIG. 10A) or ONBK (FIG. 10C). 
Extremely weak signals were detected in samples without 
unnatural amino acids, which indicated an acceptable fidel 
ity and efficiency. 
0093. Next, HIV-1 viability was tested after UV treat 
ment. After being exposed to 365 nm UV light for 0, 5, 10, 
20, or 30 minutes, HIV-1 viruses ware applied to TZM-bl 
cells and the infectivity of the viruses were examined No 
obvious detrimental effects were observed for the UV 
treated Samples compared with non-treated control (0 min 
ute sample). It was concluded that 365 nm UV light does not 
reduce virus infectivity. 
0094 ONBY and ONBK have been successfully incor 
porated into essential HIV-1 proteins, including the group 
specific antigen (Gag) and the protease. 
Example 17 
In Vivo Control of HIV Replication in a 
Humanized Mouse 
0095 To evaluate the live, attenuated HIV vaccine, the in 
Vivo replication capacity and kinetics of the vaccine are 
examined in humanized mice (hu-BLT mice). The Hu-BIT 
mouse can reconstitute all major human hematopoietic lin 
eages, including CD4+, CD8+T, B, monocyte/macrophage, 
dendritic and natural killer cells in both mucosal and sec 
ondary lymphatic tissues. Hu-BLT mice are generated from 
SEQUENCE LISTING 
<16 Os NUMBER OF SEO ID NOS: 23 
<21 Os SEQ ID NO 1 
&211s LENGTH: 25 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs SEQUENCE: 1 
ctagaacgat tcgcagttaa cc ctd 
<21 Os SEQ ID NO 2 
&211s LENGTH: 37 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs SEQUENCE: 2 
gttctgcact at aggctaat tttggctgac Ctggctg 
Dec. 29, 2016 
6-8 week old female NSG (NOD/scid-ycnull) mice (Stock 
Number 005557, Jackson lab). 
0096. Three groups of hu-BLT mice (n=5) are exposed to 
a) wild-type pSUMA, b) pSUMA-tRNA-aaRS 
Trp36Gln127 (a pSUMA-Trp36Gln127 variant that contains 
a genomic copy of Suppressor tRNA and the corresponding 
aminoacyl-tRNA synthetase genes) with UAA*, or c) 
pSUMA-tRNA-aaRS-Trp36Gln127 without UAA*, and 
examined After intraperitoneal (i.p.) inoculation of virus at 
10x10, TCIDso UAA* is administered intraperitoneally to 
hu-BLT mice in the “pSUMA-tRNA-aaRS-Trp36Gln127 
with UAA group'. The plasma viral load of HIV-1 RNA in 
mice is monitored using real time qRT-PCR assay to deter 
mine if replication of pSUMA-tRNA-aaRS-Trp36Gln127 is 
tightly controlled with the availability of UAA*. The wild 
type pSUMA is used as a positive control. 
0097. It is to be understood that, while the methods and 
compositions of matter have been described herein in con junction with a number of different aspects, the foregoing 
description of the various aspects is intended to illustrate and 
not limit the scope of the methods and compositions of 
matter. Other aspects, advantages, and modifications are 
within the scope of the following claims. 
0.098 Disclosed are methods and compositions that can 
be used for, can be used in conjunction with, can be used in 
preparation for, or are products of the disclosed methods and 
compositions. These and other materials are disclosed 
herein, and it is understood that combinations, Subsets, 
interactions, groups, etc. of these methods and compositions 
are disclosed. That is, while specific reference to each 
various individual and collective combinations and permu 
tations of these compositions and methods may not be 
explicitly disclosed, each is specifically contemplated and 
described herein. For example, if a particular composition of 
matter or a particular method is disclosed and discussed and 
a number of compositions or methods are discussed, each 
and every combination and permutation of the compositions 
and the methods are specifically contemplated unless spe 
cifically indicated to the contrary. Likewise, any Subset or 
combination of these is also specifically contemplated and 
disclosed. 
25 
37 
US 2016/0375128A1 
10 
- Continued 
<210s, SEQ ID NO 3 
&211s LENGTH: 24 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 3 
tagcctatag togcagaacct c cag 
<210s, SEQ ID NO 4 
&211s LENGTH: 24 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 4 
gtgcctatag citttgttgtcc acag 
<210s, SEQ ID NO 5 
&211s LENGTH: 25 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
< 4 OO SEQUENCE: 5 
ctagaacgat t cqcagttaa ccctg 
<210s, SEQ ID NO 6 
&211s LENGTH: 4 O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 6 
titt.cctg.cgt cagcctatgc titgctgtgct tttitt cittac 
<210s, SEQ ID NO 7 
&211s LENGTH: 23 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OO > SEQUENCE: 7 
Ctgacgcagg aaacaa.ca.gc cag 
<210s, SEQ ID NO 8 
&211s LENGTH: 24 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 8 
gtgcctatag citttgttgtcc acag 
<210s, SEQ ID NO 9 
&211s LENGTH: 27 
24 
24 
25 
4 O 
23 
24 
Dec. 29, 2016 
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&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 9 
caaagtaaga caatatgatc aggtaac 
<210s, SEQ ID NO 10 
&211s LENGTH: 29 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 10 
cacctic taca gatgttct ct cagttcctic 
<210s, SEQ ID NO 11 
&211s LENGTH: 28 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 11 
Catctgtaga ggtggggatt taccacac 
<210s, SEQ ID NO 12 
&211s LENGTH: 24 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 12 
gct tcc catgtttct ctittg tatg 
<210s, SEQ ID NO 13 
&211s LENGTH: 25 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 13 
ctagaacgat t cqcagttaa ccctg 
<210s, SEQ ID NO 14 
&211s LENGTH: 43 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 14 
atttctatgg ttacct gatc ctattgtc.tt actittgataa aac 
<210s, SEQ ID NO 15 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
27 
29 
28 
24 
25 
43 
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<4 OOs, SEQUENCE: 15 
gtagaggat C Cactagtaac 
<210s, SEQ ID NO 16 
&211s LENGTH: 36 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 16 
tagctic cctd cittgcctata ctatatgttt taattg 
<210s, SEQ ID NO 17 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 17 
ggcaa.gcagg gagctagaac 
<210s, SEQ ID NO 18 
&211s LENGTH: 24 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 18 
gtgcctatag citttgttgtcc acag 
<210s, SEQ ID NO 19 
&211s LENGTH: 22 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 19 
gctatalagac gcgt.ccacca t 
<210s, SEQ ID NO 2 O 
&211s LENGTH: 19 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 2O 
Cctaggtggc atcgcc ct c 
<210s, SEQ ID NO 21 
&211s LENGTH: 34 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 21 
cgatgccacc tagggaaagc tigacic ctgaa gttc 
36 
24 
22 
19 
34 
Dec. 29, 2016 
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- Continued 
<210s, SEQ ID NO 22 
&211s LENGTH: 26 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic oligonucleotide 
<4 OOs, SEQUENCE: 22 
cgt.ctagatt acttgtacag ct catc 
<210s, SEQ ID NO 23 
&211s LENGTH: 16 
212. TYPE: PRT 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: synthetic peptide 
<4 OOs, SEQUENCE: 23 
26 
Phe Ser Val Ser Gly Glu Gly Glu Gly Asp Ala Thr Ala Phe Gly Lys 
1. 5 10 
1. A live, attenuated HIV vaccine, wherein the genome of 
the HIV comprises at least one first mutation in an essential 
region, wherein the first mutation is a nonsense mutation. 
2. The live, attenuated HIV vaccine if claim 1, wherein the 
essential region is the protease gene. 
3. The live, attenuated HIV vaccine of claim 1, wherein 
the genome of the HIV further comprises at least one 
transgene in a non-essential region, the transgene encoding 
a Suppressor tRNA and a corresponding aminoacyl-tRNA 
synthetase. 
4. The live, attenuated HIV vaccine of claim 3, wherein 
the non-essential region is between the env gene and the nef 
gene. 
5. The live, attenuated HIV vaccine of claim 1, wherein 
the genome of the HIV further comprises at least one second 
mutation in an essential region, wherein the second mutation 
results in a codon encoding for an unnatural amino acid, 
wherein the unnatural amino acid is a photoreactive amino 
acid. 
6. The live, attenuated HIV vaccine of claim 5, wherein 
the photoreactive amino acid is a photocaged amino acid. 
7. The live, attenuated HIV vaccine of claim 6, wherein 
the photocaged amino acid is selected from the group 
consisting of ONBK and ONBL. 
8. The live, attenuated HIV vaccine of claim 5, wherein 
the essential region is the gag gene or the protease gene. 
9. A method of making a live, attenuated HIV vaccine, 
comprising: 
infecting a host cell with the live, attenuated HIV vaccine 
of claim 1; and 
purifying the live, attenuated HIV vaccine. 
15 
10. The method of claim 9, further comprising exposing 
the infected host cell to light. 
11. The method of claim 10, wherein the light is UV light. 
12. The method of claim 11, wherein the UV light is 365 
nm light. 
13. The method of claim 9, wherein the host cell com 
prises at least one transgene encoding a Suppressor tRNA 
and a corresponding aminoacyl-tRNA synthetase. 
14. An article of manufacture for producing a live, attenu 
ated HIV Vaccine, comprising: 
the live, attenuated HIV vaccine of claim 1; and 
at least one unnatural amino acid (UAA). 
15. The article of manufacture of claim 14, further com 
prising a host cell. 
16. The article of manufacture of claim 15, wherein the 
host cell comprises at least one transgene encoding a first 
suppressor tRNA and a first corresponding aminoacyl-tRNA 
synthetase pair that recognizes the unnatural amino acid. 
17. The article of manufacture of claim 16, further com 
prising a photoreactive amino acid. 
18. The article of manufacture of claim 14, wherein the 
UAA* is a photoreactive amino acid. 
19. The article of manufacture of claim 17, wherein the 
host cell further comprises at least one transgene encoding 
a second Suppressor tRNA and a second corresponding 
aminoacyl-tRNA synthetase pair that recognizes the photo 
reactive amino acid. 
